NasdaqGM:MIRMBiotechs
What Mirum Pharmaceuticals (MIRM)'s Volixibat PSC Trial Win and $600M Notes Deal Means For Shareholders
Earlier in May 2026, Mirum Pharmaceuticals completed a US$600,000,000 zero-coupon senior unsecured convertible note offering due June 1, 2032, while also reporting a quarterly net loss of US$790.16 million and raising 2026 net product sales guidance to US$660 million–US$680 million.
The company also reported that its VISTAS Phase 2b trial of volixibat in primary sclerosing cholangitis met its primary endpoint, reinforcing the potential for the drug to address an area with no approved PSC...